Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback